Acute exposure to hydrogen sulfide (H 2 S) causes 4 dose-dependent responses: hyperpnea, unconsciousness or knockdown, apnea, and death. At present, scientific mechanisms for these effects are unknown, but inhibition of cytochrome oxidase in the central nervous system (CNS) by sulfide has been suggested. In this study, the premise of brain as target is examined by comparing peripheral with direct delivery of sulfide to brain. NaHS was administered to anesthetized Sprague-Dawley male rats, by femoral intravenous, or carotid intra-arterial injection. With apnea as the test, ED 100 values of 0.6 and 3.0 mg kg -1 were found for peripheral and direct delivery to brain, respectively. Peripheral delivery is 5 times as effective as direct delivery to the brain, and greater if the relative dilution factors are considered. Lidocaine, applied to the vagus, prevented apnea, so lung-brain transmission was essential. It was therefore concluded that the lung is the peripheral site of action. Hyperpnea increased in duration with dose. The carotid body, located distal to the arterial catheter, sensed the high doses of NaHS but did not trigger apnea. Intravenous infusion or intraperitoneal injection with NaHCO 3 prevented hyperpnea, apnea, and death. The following conclusions are drawn: the carotid body is not implicated in NaHS-induced apnea, the lung and not brain harbors the primary site of action of H 2 S, and an afferent neural signal from the lung via the vagus induces the apnea. Finally, NaHCO 3 appears to prevent toxicity from sulfide, and therefore H 2 S, by some unexplained mechanism. Practical emergency treatment for acute toxicity in the field may be possible.
Hydrosulfide (HS -) is the active ion released from H 2 S, NaHS, or Na 2 S and is a toxic hazard in many modern places of work (Finklea, 1977; Hoffman and Guidotti, 1997) . By definition (World Health Organization (WHO), 1981) , effects from exposure to HS -may become chronic, as from repeated low doses, or acute, from a single massive dose. The early symptoms of exposure, not readily quantifiable, include "gas eye," sore throat, dizziness, nausea, and respiratory effects attributed to airway irritation (Guidotti, 1996; WHO, 1981) . The exposure-response relationship for acute exposure to HS -is very steep, especially for CNS and respiratory effects (Guidotti, 1996; WHO, 1981) , but 4 precise events can be identified. At about 200 ppm, HS -induces an abrupt and reversible episode of unconsciousness, which is called "knockdown" in the workplace (Guidotti, 1996) . Concentrations of 1000 ppm cause knockdown and respiratory paralysis, which can lead to death. At 2000 ppm or greater, knockdown, apnea, and then death occur rapidly. Cardiac function persists through the apnea, excluding the heart as an end organ of HS -toxicity (Haggard, 1925; Torrans and Clemens, 1982) . Lethality is thought to be due to paralysis of the respiratory center in the brain stem (Haggard, 1925) ; it is widely believed that the inhibition of cytochrome oxidase in the brain is implicated in the mechanism (Beauchamp et al., 1984; Reiffenstein et al. 1992b; WHO, 1981) . The fourth event, hyperpnea, occurs just before apnea and is thought to be mediated by pulmonary endings of the vagal nerve (Haggard, 1925) .
The perceived similarity between intoxication by potassium cyanide (KCN) and H 2 S (Haggard, 1925) , and the similarity in the inhibition of cytochrome oxidase by these agents (Keilin and Hartree, 1939) underlie the importance of cytochrome oxidase in the mechanism of HS -toxicity. The molecular interaction of cytochrome oxidase with HS -has been characterized but a direct link between enzyme inhibition and apnea has not been established. (Nicholls, 1975; Nicholls et al., 1976; Wever et al., 1975) . In fact, more than 30 enzymes are inhibited by HS - (Khan et al., 1989) , but there is no compelling evidence that any is a target for end-organ toxicity.
A comparison of function after exposure to cyanide showed that inhibition of the respiratory activity on the one hand, and the enzyme activity from isolated brain mitochondria on the other, lacked correlation (Pettersen and Cohen, 1993) . The authors suggested that cytochrome oxidase may not be the target enzyme for cyanide. By analogy, its involvement in the toxicity of HS -must also be questioned. In an attempt to link the brain stem with toxicity, sulfide concentrations were measured in the different regions of the brain. After a supra-lethal dose of HS -, the brain stem had the highest level of sulfide among the regions examined (Warenycia et al., 1989) . Unfortunately, a comparison with other organs was not made; an earlier study had already shown that the concentration of sulfide in the gills of fish exposed to H 2 S exceeded that in the brain, and that apnea preceded loss of cardiac function (Torrans and Clemens, 1982) .
The effects of HS -on respiratory rhythms were examined in an in-vitro study . Direct application of HS -to the isolated brain stem preparation (Suzue et al., 1983) did not inhibit spontaneous respiratory rhythm except at concentrations exceeding an equivalent in-vivo lethal dose. A similar result was obtained with cyanide (Greer and Carter, 1996) . Therefore, direct inhibition of cytochrome oxidase in the brain stem by HS -or cyanide may occur, but apparently does not ablate respiratory rhythms.
Apnea is a characteristic response to inhaled pulmonary irritants, so it is likely that the lung is a target for HS -toxicity. Chemical irritant receptors on lung have been commonly studied with substances such as phenyldiguanide and capsaicin. These receptors have been variously named as J or pulmonary capillary receptors, alveolar nociceptors, and pulmonary Cfibers. The literature has been well-reviewed (Coleridge and Coleridge, 1986; Sant' Ambrogio, 1987) . The characterization of C-fibers in the lung has employed a variety of physiological methods including the recording of electrical activity from single neurons in the vagus (Coleridge and Coleridge, 1981; Iggo, 1958) . Studies have shown that chemical irritants injected in the femoral vein, the right atrium, or the pulmonary artery caused immediate apnea in dogs, but failed to depress respiration if injected into the left atrium (Coleridge et al., 1964; Dawes et al., 1951; Paintal, 1955; Porszasz et al 1957; Toh et al. 1955) . That is to say, respiratory block results if the irritant is delivered to the lung but not to the brain. This site-directed method is used in this study, to compare the sensitivities of lung and brain to HS -. These nerve endings are also stimulated by an increase in CO 2 (Delpierre et al. 1981; Trenchard 1986) , which implicates carbonic anhydrase, an enzyme that is inhibited by mercaptans (Schwimmer, 1969) . The in-vitro I50 by HS -for beef red blood cell carbonic anhydrase (from Sigma Chemical Co.) was 1.5 M (authors' unpublished data). This study examines the hypothesis that apnea is induced by a peripheral site, probably in the lung. The effects of parenteral NaHCO 3 are also examined. A preliminary account of these studies has been communicated (Almeida and Guidotti, 1996) .
MATERIALS AND METHODS
Chemicals. All chemicals were used as aqueous solutions. The NaHS (Aldrich Chemicals) in solution, ϳ1.0 M, was quickly prepared and stored as 0.5-ml aliquots sealed in 1-ml glass ampoules, under nitrogen, to prevent the rapid decomposition of NaHS. The concentration was determined by iodometric assay and remained constant for up to 2 years with the ampoules stored at room temperature. A fresh ampoule was used for each experiment. Urethane (Sigma), 1.5 g/kg -1 was used for general anesthesia, and lidocaine (Sigma), a neutral 1% saline solution of the hydrochloride, for topical application to the vagus. NaHCO 3 (Fisher Scientific), 1.4%, was prepared and filtered (Millipore, 0.22 l daily}.
Animals. Sprague-Dawley male rats, 300 -350g, were obtained from the Health Sciences Lab Animal Services of the University of Alberta. The animals are bred and nurtured on the premises, and were ordered singly. The use of animals was approved by the Health Sciences Animal Welfare Committee of the University of Alberta which adheres to the requirements of the Canadian Council on Animal Care.
Methods. Animals anesthetized with urethane, 1.5 g/kg -1 , ip, were maintained in surgical anesthesia throughout the experiment. Cannulae were installed in a femoral vein or a carotid artery for the administration of fluids, and in the trachea for monitoring respiration. Records of respiration were made on a Beckman Type RB Dynograph, with signals from a conditioner (CD-15) linked to a Validyne transducer (DP103 Ϯ 0.1 psi). The HS -, a few microliters, followed by 0.5 ml saline, was administered as a bolus by femoral intravenous (fiv) or by carotid intra-arterial (cia) injection. Apnea lasting for 2 s or longer was defined as positive. Anesthetized animals with no surgical intervention were also used in some studies. In these cases, animals received ip injections only, and the respiration was recorded from a whole body plethysmographic chamber with a volume of 2.4 liters and an air flow of not less than 300 ml/min -1 . A recovery period of 1 h after surgery, and 30 min between incremental doses of HS -was allowed. No animals received duplicate doses. For all studies with NaHCO 3 , a lethal dose of HS -was administered ip. The antidote, NaHCO 3 , was administered by intravenous infusion (0.1 ml/min -1 , 17 mol/min -1 ), and commenced just prior to, or by intraperitoneal pretreatment injection (2-2.5 ml, 333-400 moles), given 2 min before, the lethal dose of HS -(30 mg kg -1 ip) (according to the method of Warenycia et al., 1989) . For the study of vagal paralysis, a test dose of HS -was given by fiv injection prior to treatment with lidocaine, to obtain a control response. The vagi in the region of the neck (C2-C4), were blotted with cotton swabs, and lidocaine (1%, 10 -20 l) applied to each side. The onset of the effect of lidocaine was determined by trial and error, using the minimal number of doses of HS -. In this manner, traces were obtained that showed the effects of the same dose of HS -, before, during, and after treatment with lidocaine. The effect of lidocaine on blood pressure and heart rate was monitored in a few animals, using a pressure transducer linked to a catheter in a femoral artery and to the Dynograph. Lidocaine had no effect on heart rate or blood pressure in the dosage at which it was used.
Quantification. The quantification of data from in-vivo studies of respiration is subject to many variables including the size of the rat, the sizes of heart and lung, the blood hemoglobin content, and the tidal volume. Other individual differences include the sensitivity of the animal to the HS -and to the anesthetic. Finally, the depth of anesthesia is also an important factor in respiratory function. Therefore, the following method of quantification was used.
Apnea and death being all-or-none events, the use of ED and LD values were readily applicable. Quantification of hyperpnea (␦H) was achieved by expressing its duration as a percentage of the sum of the duration of hyperpnea and apnea. Therefore, the value for hyperpnea will lie between 100, the reading for hyperpnea without apnea, and 0, the reading for apnea and death without hyperpnea.
RESULTS

Comparison of Sensitivity to HS -after Peripheral Administration and after Direct Delivery to the Brain
Incremental single doses, beginning with 0.1 mg kg -1 , were administered by femoral intravenous (fiv) injection so the HS -would pass through the heart to the lung, assumed to be a likely site of action. To test the sensitivity of the brain, similar incremental doses were administered by carotid intra-arterial (cia) injection; in this case the HS -would enter the brain directly. The results, shown in Figure 1a for fiv injection and Figure 1b for cia injection, depict traces from a single animal for each case. The arrowheads indicate the point of injection, and the time bar below the last trace indicates ten s. The fiv injection of saline alone, as shown by the arrow above the topmost trace in Figure 1a , shows no effect on respiration. The lowest dose of HS -, 0.2 mg kg -1 , caused a brief hyperpnea of about 20 s with no apnea. With 0.4 mg kg -1 HS -, this hyperpnea was followed by apnea, which lasted for about 4 sec. The duration of apnea increased with the dose. Thus, the threshold dose for apnea was 0.4 mg kg -1 and the ED 100 (100% of animals had apnea) was 0.6 mg kg -1 . The concentration of HS -required for apnea varied from greater than 0.2 to 0.6 mg kg -1 HS -, reflecting a difference in sensitivity of the animals to this toxin. The cumulative result from this study of the incidence of apnea is shown in Table 1 . The dose curve is steep with a dose range (ED 100 -ED 0 ) of 0.3 mg kg -1 . Representative traces from direct delivery of HS -to the brain by cia injection are shown in Fig 1b. Unlike the previous experiments, saline alone caused a short-lived increase in the rate and amplitude of respiration that was qualitatively distinct from the HS --induced hyperpnea. The lowest dose of HS -required for the induction of apnea by cia administration was not less than 1.5 mg kg -1 . The accumulated data from these experiments are also shown in Table 1 . The dose curve is less steep than before, with a range from threshold to ED 100 of 1.5 mg kg -1 . When compared, using ED 100 values (0.6 mg kg -1 and 3.0 mg kg -1 ) and the dose range (0.3 and 1.5 mg), fiv administration is at least 5 times as effective as cia administration.
Lung-Brain Communication for Induction of Apnea
The dilution factor for HS -reaching the brain stem by fiv administration is markedly greater than the more direct cia route; therefore the true sensitivity of the lung is greater than the 5-fold difference described above. Mediation of apnea by the lung is likely to be along non-myelinated vagal afferents (Coleridge and Coleridge, 1986 ). This hypothesis was tested as follows: lidocaine was applied topically to the vagi and its effects on apnea from HS -were determined. The topical application of lidocaine did not affect blood Table 1. pressure or heart rate, and traces have not been shown here. Figure 2 shows that lidocaine alone had no effect on respiration. The fiv injection of a fixed dose of HS -, 0.4 mg kg -1 , after lidocaine treatment, produced a gradual decrease in the duration of apnea. The control value of about 12 s fell to about 7 s after 9.5 min and was completely abolished in 15 min. This onset of vagal anesthesia varied from 10 to 22 min (see Table   2 ) in the 5 animals that were tested. The effect of lidocaine was temporary and vagal transmission was completely restored, as seen from the return of apnea (see Table 2 ). The duration of vagal paralysis also varied between animals.
Hyperpnea Induced by HS -
Hyperpnea is an increase in rate and amplitude of respiration. Figure 1a shows the effects of HS -after fiv administration. If examined singly, hyperpnea and apnea both increase in duration with dose. However, if present together, hyperpnea decreases with increasing duration of apnea. The highest dose, 1.0 mg kg -1 HS -, produced the shortest hyperpnea and the longest apnea. Using the quantification method described above, this inverse correlation is shown as values of ␦H in the legend of Figure 1a .
Data from the studies with lidocaine, as shown in Figure 2 and Table 2 , also enabled characterization of hyperpnea from HS -. Although a constant dose of HS -was used, 0.4 mg kg -1 , the duration of hyperpnea did not remain constant but increased as the apnea decreased (see Fig. 2 ). The ␦H values derived for these changes are presented in Table 2 . The control column shows a range of values for ␦H that reflects the variation in sensitivity to HS -. With the onset of lidocaine action, the duration of apnea decreases and that of hyperpnea increases. All 5 animals showed an increase in ␦H with time, to a maximal value of 100. As the effect of lidocaine was eroded, ␦H decreased, which corresponded to a return of the apnea.
In the case of cia injection (Fig. 1b) , the effect of HS -on hyperpnea and apnea is qualitatively similar to fiv treatment. At the highest dose tested however, the hyperpnea is markedly diminished, giving the false appearance of a direct inhibitory effect on the carotid.
Effects of Bicarbonate on Lethal HS -
The lethal dose of NaHS for Sprague Dawley rats, the LD 100 , was assessed at 30 mg kg -1 (Warenycia et al., 1990) , but the effects on respiration were not reported. Figure 3a shows an example of the pattern of respiration of an anesthetized rat that was given NaHS, 30 mg kg -1 ip. Within a minute, there was a marked hyperpnea; the respiratory rate increased from about Table 2. 1.9 sec -1 to about 3.0 sec -1 , with a noticeable increase in amplitude and occasional gasping. Shortly thereafter, the rate decreased and the amplitude increased, leading then to apnea and death. Figure 3b is a continuous trace from an animal that received NaHCO 3 by iv infusion (first arrowhead) along with HS -, 30 mg kg -1 ip (second arrowhead). The NaHCO 3 alone, as shown by the first arrow, had no affect on hyperpnea or on respiration. After ip injection of HS -, there was no evidence of the toxic effects of this agent (see Fig. 3a ). Occasional gasping was still present but the hyperpnea, apnea, and death were prevented in all animals tested. A similar result was obtained with a second group of animals pretreated with NaHCO 3 , 2-2.5ml, given intraperitoneally 2 min before the HS -. The cumulative data obtained from the examination of the effects of NaHCO 3 on the toxicity of HS -are presented in Table 3 . Whether given by simultaneous iv infusion or by ip pretreatment, the NaHCO 3 prevented death in all animals that were studied. From these experiments, the mechanism is unclear but the importance of NaHCO 3 is established, as an agent for the study of HS -toxicity and for the elucidation of treatment protocols.
DISCUSSION
The injection of sulfide, 0.6 mg kg -1 , into a peripheral vein, despite subsequent mixing and dilution by cardiac output, produced an apneic response in 100% of animals tested. In contrast, direct carotid artery injection of more than a 3-fold increase in dose, 2.0 mg kg -1 , produced apnea in only 30% of animals tested. In the former case, that is after peripheral injection, dilution alone would reduce the effective drug concentration to the brain by a factor of 5. It is therefore unlikely that apnea is the consequence of a direct effect on the brainstem. A peripheral signal mediating a central response is a better explanation for the apnea. Most probably, this would occur by a reflex mechanism with non-myelinated vagal afferents in the lung (Coleridge and Coleridge, 1986) . This interpretation is supported by the observation that apnea is prevented, after disruption of the vagal connection by local anesthesia with lidocaine. Variability in duration and time of onset of vagal paralysis may be a consequence of individual variation in the rate of biotransformation of the lidocaine.
The currently accepted theories of the mechanism of action of HS -, as reflected in the literature (Beauchamp et al., 1984; Reiffenstein et al. 1992b; WHO, 1981) , are not in agreement with the conclusions made here, but there are precedents for it. Binding studies conducted with brain microsomal membranes showed that sub-millimolar concentrations of HS -did not affect the binding of glutamate or GABA, the neurotransmitters of greatest abundance in the brain (Reiffenstein et al., 1992a) . In vivo studies on rats showed that a 30-s time delay exists between the onset of apnea and the inhibition of electrical activity in the hippocampus after iv administration of a sub-lethal dose of HS - (Reiffenstein et al., 1993) . Studies also showed that the respiratory rhythms of the isolated brain stem preparation (Suzue et al., 1983) are not inhibited by HS -except at doses in excess of a lethal equivalent dose . Thus, it appears that mechanisms acting apart from the respiratory center in the brain stem are first to act in response to HS -. It also appears that at least within the range of toxicological interest, intact neuronal contact between brain and some peripheral site is necessary if apnea is to be elicited.
The use of a physiological in-vivo model in these studies has enabled a direct examination of hyperpnea. Changes in blood chemistry detected by the carotid body signal the respiratory center towards an increase or decrease in respiration (Lahiri et al. 1991) . A bolus injection of saline dilutes the blood and shown by the first arrow and followed by HS -, 30 mg kg -1 ip, shown by the second arrow, prevented the increase in rate and amplitude of respiration, as well as the apnea and death (n ϭ 4; p Ͻ 0.02, compared to control animals). A similar result (not shown) was obtained with NaHCO 3 pretreatment, 2-2.5 ml given ip, 2 min before lethal HS -(n ϭ 6; p Ͻ 0.0005, compared to control animals). Collated data from these experiments are shown in Table 3. alters its chemistry, so contact with the carotid body should activate its chemoreceptors. Since the tip of the catheter to the carotid artery was placed proximal to the carotid body, any dilution of the blood from an intracarotid arterial injection of saline would be reported promptly by this organ and this is indeed the case (Fig. 1) . In contrast, the hyperpnea from a femoral vein injection would be attenuated because considerable mixing would occur prior to contact with the carotid body, and this contrast is also apparent from the data (Fig. 1) . These differential effects of saline by the 2 injection sites would also apply to the HS -injection (Fig.1) . That is to say, if the carotid body induces apnea, a carotid arterial dose should be more potent; in fact, this is not the case. Therefore, HS -may act on the carotid body but the latter does not trigger apnea.
Hyperpnea was recognized as a symptom of HS -intoxication relatively early (Haggard, 1925) . Low doses cause hyperpnea; at moderate doses, it is followed by apnea. At the highest doses, knockdown and apnea are practically instantaneous with no sign of hyperpnea. Haggard (1925) described a correspondence between the dose of HS -and the duration of hyperpnea, and offered the interpretation that the apnea of moderate doses of HS -was a compensatory action for respiratory alkalosis and hypocapnia. He noted that apnea in this case was distinct from the apnea of high doses that led to death without hyperpnea. He attributed the apnea in the latter case to a direct effect of HS -on the brain stem. The data presented here show that an increase in hyperpnea with dose of HS -occurs only if apnea is absent. In the presence of apnea, this correlation is reversed; the duration of hyperpnea decreases as the duration of apnea increases. That HS -activates the carotid chemosensor is undisputed, and this is manifested as a change in respiration. In the absence of respiratory drive, chemosensor function cannot be monitored. The data of Figure 2 shows that the prevention of apnea by vagal paralysis prolongs hyperpnea.
Recently an alternative suggestion was made, namely that HS -acts on cytochrome oxidase to cause hypoxia, which is sensed as low oxygen tension by the carotid and aortic chemoreceptors (Ammann, 1989) . The explanatory power of this suggestion is considerably diminished by the absence of supporting data and the weakness of the cytochrome hypothesis (Pettersen and Cohen, 1993) . This mechanism is also not supported by our data.
The relative sensitivities of the brain and the peripheral site can be determined by comparing the effective dose required to elicit the apneic response. The ED 100 values for carotid artery injection and femoral intravenous injection are 3.0 mg kg -1 and 0.6 mg kg -1 , respectively. As determined by the range of concentration from the dose curve for apnea, the relationship between total dose per animal for each mode of administration is on the same order, 1.5 mg and 0.3 mg. It is estimated that the sensitivity of the lung to infused HS -is greater than 5 times that of the brain, a further argument for a peripheral site of action.
Except for assisted ventilation, the current treatment modalities for acute HS -exposure are of questionable value (Guidotti, 1996; Herbert, 1989; Vicas, 1989) . The use of sodium nitrite (Smith et al., 1976) , glutathione (Smith and Abbanat, 1966) , or dithiothreitol (Warenycia et al., 1990) as antidotal agent is based on the suggestion that HS-and cyanide share a common mechanism of toxic action and this is currently untenable (Peterssen and Cohen, 1993) .
In 1938, Meshenin reasoned that the best treatment for HS -toxicity would be the removal of the toxin by oxidation with peroxide, and neutralization of the acid formed with NaHCO 3 . He reported a marked reduction in mortality to HS -for dogs infused with a 1% solution of NaHCO 3 containing 0.5%hydro-gen peroxide. Our data suggest that NaHCO 3 and not peroxide prevented death. The prevention of apnea as well as death by NaHCO 3 suggests that death in acute exposure may be a consequence of prolonged reflex apnea and not a direct effect of HS -on the respiratory center as previously postulated (Haggard, 1925) .
The certainty of the results from the studies with NaHCO 3 though impressive does not proffer a mechanism for the prevention of hyperpnea, apnea, and death from HS -. As was discussed earlier, the inhibition of carbonic anhydrase by HS -is possible (Schwimmer, 1969) , but an association between this interaction and NaHCO 3 remains to be explored.
The involvement of carbonic anhydrase in the induction of apnea is also important. Acetazolamide, which inhibits carbonic anhydrase, is known to cause a 5-fold decrease in catalytic rate (Klocke, 1978) ; such a transient increase in CO 2 can trigger respiratory reflexes by activating non-myelinated vagal afferent endings (Trenchard, 1986) . Therefore, it is possible that the inhibition of carbonic anhydrase by HS -may be a part of the mechanism in the antidotal effects of NaHCO 3 .
This study has shown that the effect of HS -in the production of apnea may occur by a peripheral mechanism involving the lungs and that the infusion of bicarbonate is an effective preventive treatment for lethal apnea induced by HS -. These two observations may lead to a safe and effective treatment for human toxicity due to H 2 S.
The characteristics of an effective treatment must conform to the realities of workplace and community exposure. It must be readily supplied and distributed in the field, bio-available without on-site preparation, easily stored without refrigeration or special measures, suitable to be administered by untrained co-workers, and fast acting. Bicarbonate appears to have some of these characteristics. The need for intravenous injection is most problematical. Further investigation of the phenomenon of bicarbonate rescue suggests a practical treatment with the potential to be lifesaving.
